NCT05216224 - ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

December 23, 2022

Study Completion Date

January 24, 2023

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

ATI-450

Oral, small molecule MK2 inhibitor

DRUG

Placebo oral tablet

Placebo tablet manufactured to match ATI-450 in appearance

Trial Locations (20)

17033

Aclaris Investigational Site, Hershey

28277

Aclaris Investigational Site, Charlotte

29621

Aclaris Investigational Site, Anderson

30060

Aclaris Investigational Site, Marietta

30328

Aclaris Investigational Site, Sandy Springs

33021

Aclaris Investigational Site, Hollywood

33486

Aclaris Investigational Site, Boca Raton

33613

Aclaris Investigational Site, Tampa

35244

Aclaris Investigational Site, Birmingham

37215

Aclaris Investigational Site, Nashville

45040

Aclaris Investigational Site, Mason

45701

Aclaris Investigational Site, Athens

48059

Aclaris Investigational Site, Fort Gratiot

70006

Aclaris Investigational Site, Metairie

72916

Aclaris Investigational Site, Fort Smith

77054

Aclaris Investigational Site, Houston

77478

Aclaris Investigational Site, Sugar Land

91436

Aclaris Investigational Site, Encino

Aclaris Investigational Site, Thousand Oaks

94115

Aclaris Investigational Site, San Francisco